申请人:PTC Therapeutics, Inc.
公开号:EP3111956A1
公开(公告)日:2017-01-04
The compounds, pharmaceutical compositions, and methods of using such compounds or compositions thereof described herein are useful for treating a disease modulated by B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein expression.
本文所述的化合物、药物组合物和使用此类化合物或其组合物的方法可用于治疗由 B 细胞特异性莫隆尼鼠白血病病毒整合位点 1(Bmi-1)蛋白表达调节的疾病。